hVIVO has signed a new testing contract with an Asia-Pacific based drug maker, which it says is an indication of its growing regional client base.
The UK contract research organisation (CRO) shared minimal details of the £6.8 million contract last week, explaining it would test the unnamed client’s respiratory syncytial virus antiviral candidate using its human challenge study model.
The Phase IIa trial will take place at hVIVO’s quarantine facilities in Whitechapel in the UK starting in the first half of next year. The firm also said its dedicated recruitment arm, FluCamp, will be responsible for finding volunteers.
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.